Brunel University Research Archive(BURA) preserves and enables easy and open access to all
types of digital content. It showcases Brunel's research outputs.
Research contained within BURA is open access, although some publications may be subject
to publisher imposed embargoes. All awarded PhD theses are also archived on BURA.
Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/27669| Title: | Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease |
| Authors: | Creese, B Ismail, Z |
| Keywords: | mild behavioral impairment;neuropsychiatric symptoms;preclinical AD;cognition;biomarkers |
| Issue Date: | 5-Jan-2022 |
| Publisher: | Biomed Central (part of Springer Nature) |
| Citation: | Creese, B. and Ismail, Z. (2022) 'Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease', Alzheimer's Research and Therapy, 14 (1), 2, pp. 1 - 5. doi: 10.1186/s13195-021-00949-7. |
| Abstract: | Copyright © The Author(s) 2022. Background: Late-life onset neuropsychiatric symptoms are established risk factors for dementia. The mild behavioral impairment (MBI) diagnostic framework was designed to standardize assessment to determine dementia risk better. In this Mini Review, we summarize the emerging clinical and biomarker evidence, which suggests that for some, MBI is a marker of preclinical Alzheimer’s disease. Main: MBI is generally more common in those with greater cognitive impairment. In community and clinical samples, frequency is around 10–15%. Mounting evidence in cognitively normal samples links MBI symptoms with known AD biomarkers for amyloid, tau, and neurodegeneration, as well as AD risk genes. Clinical studies have found detectable differences in cognition associated with MBI in cognitively unimpaired people. Conclusion: The emerging evidence from biomarker and clinical studies suggests MBI can be an early manifestation of underlying neurodegenerative disease. Future research must now further validate MBI to improve identification of those at the very earliest stages of disease. |
| Description: | Availability of data and materials: Not applicable. |
| URI: | https://bura.brunel.ac.uk/handle/2438/27669 |
| DOI: | https://doi.org/10.1186/s13195-021-00949-7 |
| Other Identifiers: | ORCID iD: Byron Creese https://orcid.org/0000-0001-6490-6037 2 |
| Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| FullText.pdf | Copyright © The Author(s) 2022. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | 738.58 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
